DMD

Good news.
First Patient Enrolled in Mallinckrodt's Phase 2 Duchenne Muscular Dystrophy Trial
-- Trial to Assess Efficacy and Safety of Investigational Drug MNK-1411 in Patients with DMD --
-- European Medicines Agency Grants MNK-1411 Orphan Medicinal Product Designation --
STAINES-UPON-THAMES, United Kingdom, Aug. 2, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 2 study assessing the efficacy and safety of investigational drug MNK-1411 (cosyntropin, also known as tetracosactide) in patients ages four to eight with Duchenne Muscular Dystrophy (DMD).
http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=2361608

 

Awesome ! Everyone is safe now. This is great clinical data coming.

 

The plans are in place for the outstanding future with Mnk! Believe the hype! Patients will benefit greatly from our product and we send behind the path drawing the company and those onboard closure to unique and novel product help Patint in desperate need. -cheers!

 

Thanks MT. Great leadership. Hot girlfriend